MétaCan
Menu
← Back to cohort
Record W2790910847 · doi:10.1093/jcag/gwy008.079

A78 DIRECT-ACTING ANTIVIRALS ARE NOT ASSOCIATED WITH EARLY TUMOR RECURRENCE AFTER CURATIVE TREATMENTS IN HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA

2018· article· en· W2790910847 on OpenAlexaff
Yin Chan, S Macleannan, John Wong, Elijah Dixon, Carla S. Coffin, Mark G. Swain, Kelly W. Burak

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2018
Typearticle
Languageen
FieldMedicine
TopicHepatitis C virus research
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsHepatocellular carcinomaMedicineInternal medicineGastroenterologyOncologyHepatitis C

Abstract

fetched live from OpenAlex

Interferon (IFN)-free regimens using new direct acting antivirals (DAA) have revolutionized the treatment of chronic hepatitis C (HCV) infection and demonstrate a sustained viral response (SVR) of over 90%. Recent publications have suggested an association between DAA therapy and early hepatocellular carcinoma (HCC) recurrence raising concerns about their safety. Therefore, we conducted a retrospective study to investigate the impact of DAA initiation on early tumor recurrence after curative treatments in hepatitis C-related HCC. From a combined surgery (January 2008-December 2015) and interventional radiology (January 2012-December 2015) database, 103 unique HCV infected patients with primary or recurrent HCC were identified. After excluding patients who failed to achieve complete radiological response (n=19), received transarterial chemoembolization (TACE) (n=17), received anti-viral therapy prior to HCC diagnosis or therapy (n=14), were lost to follow-up (n=7), died within 3 months of therapy (n=6), and received interferon containing DAA regimens (n=3), 37 HCV infected patients with complete response to their curative HCC therapy for at least 3 months, including 20 who subsequently received DAA therapy, were identified. With the exception of age (Control 64 years vs DAA 58 years, p<0.0133), baseline gender, total bilirubin, albumin, MELD score, alpha-feto protein levels, percentage of patients with primary HCC, and total tumor volume did not differ between the control and DAA group. Both groups were predominately infected with genotype 1 (Control 86% vs DAA 75%), while the remaining patients in the control and DAA group were infected with genotype 2 and 3, respectively. The overall median clinical remission period for the entire cohort was 26 months. Median interval between HCC treatment and the start of DAA treatment was 12.5 months, but ranged from 2 to 42 months. During a median observation time of 8 months that ranged from 2 to 20 month in the DAA group, 5 (25%) cases of recurrence were observed. Kaplan-Meier analysis showed improved probability of staying in clinical remission in the DAA group (<0.0001), even in subgroup analysis limiting the interval between HCC treatment and the start of antiviral therapy to less than 2 years. BCLC staging of recurrent disease was similar in both groups. (BCLC 0/A: Control 64% vs DAA 60%; BCLC B/C: Control 28% vs DAA 40%). In this preliminary analysis, DAA treatment after curative HCC therapy was not associated with early recurrence. Future studies using a larger cohort and longer follow up period is needed to confirm these findings. None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.257
Teacher spread0.239 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of Gastroenterology→Same topicHepatitis C virus research→French-language works237,207→